Lawrence J. Trost

Dr. Trost has 23 years nonclinical operations and development experience within the CRO, Sponsor and Consultant settings. Previous companies at which he has worked include Cato Research, Triangle Pharmaceuticals, Gilead Sciences, and Chimerix. Dr. Trost’s focus is nonclinical strategy development and implementation including study design, management and reporting across all phases of development of drugs and biologics from pre-IND through approval via 505(b)(1), 505(b)(2) and Animal Rule pathways. He has a wide range of experience and expertise, including developing drugs, biologics, devices and combination products delivered orally and by implantation, inhalation, topically, ocular, intra-articular, subcutaneous, intravenous and other parenteral routes for infectious, cardiovascular, genetic, oncology, ocular, autoimmune, respiratory, liver, CNS, bone, pain/analgesics, contraception (male and female), CBERN, endocrinology, neonatal, skin, addiction (opiate and nicotine), storage disorders and gastrointestinal diseases and indications. He has contributed to the progression of over 100 pharmaceutical candidates and 6 marketed products, including the nucleoside analogs Emtricitabine (Truvada) for the treatment of HIV and Adefovir (Hepsera) for treatment of Hepatitis B.

Dr. Trost is a Diplomat of the American Board of Toxicology. He received a Doctor of Philosophy in Toxicology from the University of North Carolina, Chapel Hill; a Master of Science Degree in Pharmacology from the University of Minnesota; and a Bachelor of Science Degree in Chemistry from the University of Minnesota.